OncoSignature + Prexasertib + Gemcitabine for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Aug 2022: Trial started, NCT05548296
  2. 21 Sep 2022: Trial registered, NCT05548296

The trials

NCT05548296: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

State
Under way
Phase
Phase 2
People
350 planned
Started
29 Aug 2022
Primary completion
30 May 2027
Arms
OncoSignature Negative Tumors
Results
None posted
  1. 29 Aug 2022: Trial started
  2. 21 Sep 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.